In June, AZ showed its Lynparza had pared down the risk of breast cancer worsening or death 42%. And that showing impressed the FDA.
Letters from patients to scientists anchor a new Pfizer-sponsored content campaign with the Boston Globe’s BG BrandLab.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
AstraZeneca wants asthma patients to know their treatment plans should be as unique and specific as their fingerprints. Its solution? Lungprint.
Keytruda has built up an imposing lead in the I-O lung cancer space, and Merck is touting more positive survival data to keep that lead intact.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Outcome Health went into crisis mode after a Wall Street Journal article said the fast-growing pharma services company had misled its advertisers.
Despite multiple late-stage failures in the past, one oncology expert believes we'll see licensed cancer vaccines within three years.
Canada has become the first country to approve GlaxoSmithKline's Shingrix, a shingles vaccine that's key to the pharma giant's sales growth.
J&J has escaped a $72 million verdict in its ongoing talcum powder saga, the first reversal of its numerous losses.
Under a growing biosim assault, Johnson & Johnson's big-selling immunology biologic Remicade held its ground again.
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.